Digital contraception is a cost-effective alternative to hormonal contraception
Digital solutions challenge established perceptions of what constitutes acceptable contraceptive methods and which health benefits are considered measurable.
In 2011 Simo Jääskeläinen was Medaffcon’s first recruitment. A couple of years ago Simo spread his wings to tackle new challenges and further develop his experience in different Market Access positions.
Simo has more than 12 years of experience from the pharmaceutical industry.
Now in June, to our great joy, Simo returned to Medaffcon, taking on the responsibility of leading our Market Access team. We are glad to welcome Simo back “home”!
At Medaffcon, this experience from the pharmaceutical and medtech industries, already exceeds 130 working years, all of which is harnessed to find the best solutions for our customers. Due to our experience and over 400 Medaffcon projects, we understand our customers’ playing field probably better than any of our competitors!

Digital solutions challenge established perceptions of what constitutes acceptable contraceptive methods and which health benefits are considered measurable.
The RWE study examined the treatment of patients with metastatic NSCLC, illustrating how treatment practices have changed from the first years of immunotherapy to present day.
The objective is to improve access to health data for research and innovation, but the proposal raises concerns about increased administrative burden and the role of industry within the model.